GlassScriptPhysician profile
Andrew M Guzman
NPI 1285606442
$1,969.84
in general payments reported to CMS, 2019-2025
24 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $45.70 · 2023: $628 · 2024: $758 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.11 |
| Education | $113.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.07 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $304.73 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Astellas Pharma US INC | $228.52 | 2023-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $214.54 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $152.23 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $143.38 | 2023-2024 | |
| Pfizer INC. | $111.99 | 2023-2025 | |
| Abbvie INC. | $73.77 | 2024 | |
| Glaxosmithkline, LLC. | $50.71 | 2023 | Trelegy Ellipta |
| Hologic Sales and Service, LLC | $43.68 | 2024 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Alnylam Pharmaceuticals INC. | $27.65 | 2025 | Givlaari |
| Sumitomo Pharma America, INC. | $26.41 | 2024 | Myfembree |
| Regeneron Healthcare Solutions, INC. | $24.62 | 2024 | Evkeeza |
| Exeltis, USA INC. | $24.46 | 2024 | Slynd |
| Amarin Pharma, INC. | $23.24 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.22 | 2024 | Truclear |
| Lilly USA, LLC | $20.50 | 2024 | Zepbound, Jardiance |
| Inari Medical, INC. | $20.31 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phathom Pharmaceuticals, INC. | $17.51 | 2024 | Voquezna |
| Amgen INC. | $16.85 | 2025 | Repatha, Otezla |
| Horizon Therapeutics Plc | $16.22 | 2019 | |
| Avion Pharmaceuticals | $16.05 | 2023 | Balcoltra |
| Nalpropion Pharmaceuticals LLC | $15.58 | 2019 | |
| Viiv Healthcare Company | $14.60 | 2025 | Apretude |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.